ESG

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Schindler's new ReStore and ReNew packages offer a cost-effective, high-tech upgrade for aging hydraulic elevators, boosting efficiency and reliability.

As Ricardé Paris claims to lead a 'Quiet Luxury' revival, the market sends mixed signals. Is understated elegance the future or a fading trend?

A new FDA-cleared system offers hope against postpartum hemorrhage, the leading cause of maternal death, earning its maker a prestigious Edison Award.

A $33M C-PACE deal for a Deepak Chopra-affiliated resort shows how innovative financing is reshaping real estate development in a tight market.

Responding to geopolitical risks, Telenor is launching a new company to provide a secure, nationally controlled cloud for Norway's most sensitive data.

BMW Group and Quantinuum expand their landmark collaboration, leveraging next-gen quantum computers to revolutionize materials for future electric and fuel cell vehicles.

A first-of-its-kind P&C product aims to protect small medical practices from unique financial risks, launched in record time on an agile insurtech platform.

A novel gene therapy aims to cross the blood-brain barrier, offering new hope for Tuberous Sclerosis Complex, thanks to a powerful new partnership.

NiSource secures top sustainability honors for over a decade. Explore how its deep ESG strategy is setting an industry benchmark and attracting investors.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

With profits up and a new CEO, TVA is pouring billions into new generation, betting on advanced nuclear power to meet soaring demand from data centers.

Atkore's Q2 revenue rose 4.2%, but a $136.5M antitrust settlement drove a major net loss. The company divests assets to focus on its electrical core.

Giyani Metals' high-purity manganese meets quality standards from US tech leader C4V, a crucial step in building a non-Chinese battery supply chain.

New research reveals CFO salaries are surging toward $4M, yet tenures are plummeting. A look at the high-risk, high-reward world of modern finance chiefs.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

UK biotech Cytospire secures a major Series A to bring its novel pan-gamma delta T cell engagers, targeting tough solid tumors, into clinical trials.

neurocare's TMS device approval marks a major shift in the Kingdom's approach to depression, prioritizing non-invasive, tech-driven solutions.